S. Hwang, H. Hong, J. Jung
Frontiers in Veterinary Science, Oct 6:12:1628931, 2025
A 7-year-old neutered male Golden Retriever diagnosed with osteosarcoma of the left radius underwent limb amputation followed by adjuvant chemotherapy utilizing alternating carboplatin-doxorubicin protocols. Following doxorubicin administration, the patient exhibited localized heat, swelling, pain, and lameness in the right forelimb, indicative of phlebitis. Ultrasonography confirmed chemotherapy-induced phlebitis with thickening of the right cephalic vein wall, intraluminal thrombi, and significant perivascular edema. Treatment involved anti-inflammatory corticosteroids, oral medications (clopidogrel, pentoxifylline, doxycycline, vitamin E), and low-level laser therapy (LLLT), achieving clinical improvement. Despite successful control of chronic inflammation in the cephalic vein, phlebitis subsequently developed in other veins, including the right common dorsal digital vein and left saphenous vein, despite varying vascular access points. The patient showed clinical improvement with the combined use of oral medication and low-level laser therapy. The chemotherapy regimen was completed successfully without osteosarcoma recurrence, and the patient remained stable for over 13 months post-treatment. Following discontinuation of chemotherapy and supportive care, no further progression of phlebitis occurred. To the authors' knowledge, this report represents the first documented veterinary case of chemotherapy-induced phlebitis in a dog. While extensively reported in human oncology, chemotherapy-induced phlebitis remains underreported in veterinary medicine. Clinicians should recognize phlebitis as a potential complication associated with chemotherapeutic agents such as doxorubicin and carboplatin. Ultrasonography serves as an essential diagnostic and monitoring tool. Prophylactic corticosteroids and adjunctive low-level laser therapy offer promising preventative and therapeutic strategies, particularly for patients with predisposed vascular inflammation. This case underscores the importance of early identification, proactive management, and individualized treatment approaches to chemotherapy-associated phlebitis in veterinary oncology.
L'accesso alla visualizzazione dei prodotti e al materiale informativo è riservato agli operatori del settore in ottemperanza alla legislazione vigente. ASA richiede di qualificarsi come operatore del settore per procedere con la navigazione.
Decreto Legislativo 24 febbraio 1997, n°46 Articolo 21
1. E' vietata la pubblicità verso il pubblico dei dispositivi che, secondo disposizioni adottate con decreto del Ministro della Sanità, possono essere venduti soltanto su prescrizione medica o essere impiegati eventualmente con l'assistenza di un medico o di altro professionista sanitario.
2. La pubblicità presso il pubblico dei dispositivi diversi da quelli di cui al comma 1 è soggetta ad autorizzazione del Ministero della Sanità. Sulle domande di autorizzazione esprime parere la Commissione di esperti prevista dall'articolo 6, comma 3, del decreto legislativo
30 dicembre 1992, n. 541, che a tal fine è integrata da un rappresentante del Dipartimento del Ministero della Sanità competente in materia di dispositivi medici e da uno del Ministero dell'Industria, del commercio e dell'artigianato.
Some of the contents of this website cannot be disclosed in the USA and its territories and possesions, for regulatory reasons. If you are a US resident, please click on the button here below and access ASA's distributor website for North America.